Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target Raised to $21.00 at LADENBURG THALM/SH SH

Corvus Pharmaceuticals (NASDAQ:CRVS) had its target price increased by LADENBURG THALM/SH SH from $12.00 to $21.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, StockNews.com raised shares of Corvus Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, September 13th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $10.83.

Corvus Pharmaceuticals Trading Down 0.4 %

Shares of CRVS opened at $5.48 on Monday. The firm’s 50-day moving average price is $3.57 and its 200-day moving average price is $2.47. The firm has a market capitalization of $342.78 million, a price-to-earnings ratio of -10.54 and a beta of 1.13. Corvus Pharmaceuticals has a 1-year low of $1.05 and a 1-year high of $6.15.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its earnings results on Tuesday, August 6th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.05. During the same quarter in the prior year, the business posted ($0.14) EPS. On average, research analysts forecast that Corvus Pharmaceuticals will post -0.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CRVS. Vanguard Group Inc. lifted its position in Corvus Pharmaceuticals by 10.6% during the 1st quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock valued at $2,658,000 after acquiring an additional 142,724 shares during the period. Towerview LLC raised its holdings in Corvus Pharmaceuticals by 4.6% in the second quarter. Towerview LLC now owns 400,000 shares of the company’s stock worth $728,000 after buying an additional 17,500 shares during the last quarter. Samlyn Capital LLC raised its holdings in Corvus Pharmaceuticals by 160.7% in the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after buying an additional 3,774,658 shares during the last quarter. Marshall Wace LLP purchased a new position in Corvus Pharmaceuticals in the second quarter worth about $136,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Corvus Pharmaceuticals in the second quarter worth about $44,000. 46.64% of the stock is owned by hedge funds and other institutional investors.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.